Cyclerion Therapeutics (CYCN) Projected to Post Quarterly Earnings on Tuesday

Cyclerion Therapeutics (NASDAQ:CYCN) will likely be releasing its results before the market opens on Tuesday, March 3rd. Analysts expect Cyclerion Therapeutics to post earnings of ($0.38) per share for the quarter.

Cyclerion Therapeutics Stock Performance

NASDAQ CYCN opened at $1.32 on Tuesday. Cyclerion Therapeutics has a one year low of $1.03 and a one year high of $3.79. The company has a 50-day simple moving average of $1.39 and a 200-day simple moving average of $1.86. The firm has a market capitalization of $5.19 million, a PE ratio of -1.76 and a beta of 0.98.

Institutional Investors Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. 75.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.